ImpediMed Limited announced a reorganisation to better align management and the organisational structure within the commercial goals of the Company. The key management roles are Shashi Tripathi ­ Chief Operating Officer: Shashi joined ImpediMed in July 2018 as Chief Technology Officer and has been instrumental
n the development of the SOZO® Digital Health Platform, leading a redesign of the user
nterface and the transition from on-premises software to a cloud-based infrastructure. In 2022,
he added Chief Customer Care to his responsibilities. His new role will now encompass all
facets of providing the SOZO Digital Health Platform, including software development, security
and customer technical support. Mike Bassett ­ Chief Commercial Officer: Mike joined ImpediMed in January 2020 as SVP Strategic and Corporate Development. Mike
originally worked on improving the Company's shareholder engagement before taking on a
broader role encompassing strategic planning, new product strategy and development of the
Renal business. Mike has a sales background and will oversee the development and execution of all commercial strategies across the Company including sales, marketing and
new business development. Dr. Thomas Schenk ­ Chief Medical Officer: Dr. Thomas Schenk, M.D. is expanding his role under his existing consulting agreement with
the Company. Tom has been working as a consultant over the past four months focusing on
the Private Pay reimbursement efforts. Now in an expanded capacity, Tom will oversee all
aspects of medical affairs to align the Company's clinical, regulatory and reimbursement
resources with its commercial goals. Dr. Schenk brings a depth of experience across patient
care, reimbursement and leadership to ImpediMed after spending the previous seven years
at BlueCross BlueShield Western New York where he served as Executive Vice President,
Chief Medical Officer. Prior to BlueCross BlueShield, Dr. Schenk served as Managing Partner
at Delaware Pediatric Associates and is a graduate of Cornell University and the University at
Buffalo School of Medicine and Biomedical Sciences. Among those leaving the Company are Dave Adams, SVP Operations and Strategic Planning, and
Dr. Frank Vicini, Chief Medical Officer (part time).